This medical market and technology report provides a comprehensive discussion of the global market for neurointerventional cerebral aneurysm and AVM embolization systems. This market comprises the following product segments: endovascular coils, liquid embolics, stents for stent-assisted coiling, flow diversion and flow disruption systems, and other novel/emerging embolization devices. Markets covered by this analysis comprise the US, Japan, the five major European markets (France, Germany, Italy, Spain, and the UK), and the rest of world (RoW) markets. The forecast range for this report is 2020–25.
In January 2015, Fortune reported that at $2.9tn, the state of the US healthcare industry is very strong and continues to grow.
The Intersection Between Tech and Pharma Special Report (Part 3. Intel, Samsung, IBM, and GE)
In January 2015, Fortune reported that at $2.9tn, the state of the US healthcare industry is very strong and continues to grow. Additionally, a Top Issues report revealed that 40% of Fortune 50 companies pursued new healthcare partnerships in 2014. Given the rapid change in the healthcare industry over the last few years, it is no surprise that we are starting to see more non-traditional healthcare partnerships, specifically with big tech companies.
Ongoing pressures on drug pricing and reimbursement mean that current research and development (R&D) economics are unsustainable. The process of discovering and developing a drug has not fundamentally changed for decades, and on average it still costs $2.6bn and takes over 10 years. Fortunately, tools are emerging to help improve R&D success rates. Most are built on better use of more kinds of data, including using artificial intelligence (AI) to process massive quantities of information that humans cannot manage. Some of these new tools promise cost and time savings of between 20–50%
Data plays a key role in healthcare systems’ shifts towards value-focused outcomes. Such data includes outcomes and cost data, adherence data, and increasingly, patient-reported data, behavioral and social media data.
Wearable technologies have the potential to transform medicine and the delivery of healthcare more significantly than any other component of the digital revolution – or indeed than many other scientific advances.
This 17-country study finds that continued growth of mobile technologies and e-commerce,combined with a more stable regulatory environment, are driving changes in the European mail order and Internet pharmacy market.
OTC drug firms should offer more digital tools that guide consumers in product purchases, says a health care marketing executive. The American Pharmacists Association suggests firms also strengthen outreach with pharmacists.
Real-world evidence promises to solve many problems inherent in getting a drug to patients at a good price. It could slash development costs and help make the reimbursement case to payers. But there are challenges for companies that want to exploit real-world evidence to get their drug to patients in Europe.
> Behind The Scenes Of Digital Health: Medtech Players And Partners > Philips To Create More Context, Connectedness And Continuity And Shift Sick Care To Health Care > New Data Gives Adherium Fuel To Accelerate Digital Tech Adoption in Drug Sector > Siemens Healthineers To Launch Digital ‘One-Stop-Shop’
> Engaging Patients and Navigating Laws: What To Consider When Developing Health Apps > Telehealth Reforms Praised At Senate Hearing > Philips’ Survey Highlights Gaps In Perceptions Of Health Care > Game On For Akili’s Cognitive Control Tech
The digital medtech sector is growing fast. As new companies enter the space, they are going to face oversight from a slew of government agencies and statutes.
> Reckitt Reaps ROI Reward In Geo-Targeted Symptoms App Promoting Mucinex, Delsym > Biogen CMO Notes iPhone’s Potential For Early Detection of Alzheimer’s > Interview: Philips Plugs Into Patient Connectivity
Funding is taking a long time to come through for the UK NHS’s digital health care transformation, but as the national provider’s head of technology strategy, Dr Paul Rice says, “We can’t afford to remain non-digital.”
Preventing cyberattacks on medical technology occupies the waking thoughts of device software manufacturers, but the global ransomware episode in mid-May shows that companies must also be alive to threat posed to their provider customers.
Sanofi plans to continue distributing Zantac OTC heartburn remedy in the US while conducting its own tests to determine whether levels of N-nitrosodimethylamine (NDMA) in the active ingredient are above safe levels, Novartis AG, which licenses OTC Zantac, has said it stopped distribution worldwide.
What’s in store for chronic disease management in the future? Tap into this informal discussion with health entrepreneur Julia Hu, founder of Lark Health, for a look at her views of what’s to come, including the use of artificial intelligence nursing.
The 21st Century Cures Act’s call for the use of real-world evidence (RWE) is slowly moving toward reality. But hurdles abound, warns IQVIA’s Nancy Dreyer. For instance, the FDA–which is behind the EMA in this area–appears split. Privacy concerns and lack of interoperability hinder progress. Learn why this sometimes-muddied distinction between randomized clinical trial data and RWE is so important, and find out RWE’s role in label expansions.
The continuous glucose monitoring (CGM) segment of the diabetes management market is exploding, while big names in the blood glucose monitoring (BGM) sector are facing increased competition from lower-cost developers and related innovative diabetes-monitoring products. Examine the competitive landscape for CGM and BGM in this informative Medtech Insight article.
In this interview with Pfizer’s head of clinical innovation, Craig Lipset, learn why clinical trial innovation requires a patient-centered approach and how Pfizer is making this happen. Learn why patient-centricity matters. Explore how the digital revolution is reshaping patient engagement, data collection and the shape of clinical trials.
At Roche’s on-site investors briefing at ASCO in 2018, company execs unveiled the oncology leader’s strategy for staying ahead in the market: heavy investment in digital and personalized healthcare. Read more about the company’s plans in this illuminating article from Scrip.
The digitalization of health care has been much talked about over the last decade or so. But activity among the medical device manufacturers and service providers has only just recently accelerated as they start overcoming barriers and resistance to this new way of delivering health care.
Abbott’s Merlin patient care network works with the CardioMEMS HF sensor system. The Merlin 10.0 update to the network allows physicians to share custom messages directly with their patients. Medtech Insight looks closer at the software and its intended benefits.
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee advises ibuprofen manufacturers to add warnings on patient information leaflets concerning acute generalized exanthematous pustulosis associated with use of the drug. HBW provides details about the skin reaction being noted and the informational changes required.
Pink Sheet spoke with Paul Goudreau, executive director & head of Phase IV Solutions at the CRO Covance, who says, “an ongoing and wide-ranging discussion is needed about assessment, payment and reimbursement of innovative products, as well as the evidence that supports them.”
The US Food and Drug Administration is considering how to respond after a contaminant was found in drugs containing, ranitidine, the active ingredient in Sanofi’s Zantac OTC heartburn remedy and multiple generic equivalents. HBW also looks at similar investigations in Europe
Knee and hip replacement company Corin Group PLC has acquired Omni Orthopedics Inc. The acquisition of Omni, which specializes in robotic-assisted total knee replacement, marks another major step in the company’s expansion in the orthopedic market.
Burt’s Bees is making another foray into the toothpaste category with a line for adults and children and a strategic licensing partnership with Procter & Gamble, makers of Crest. Discover the details of this third attempt to successfully enter the oral care space by the Clorox-owned Burt’s Bees.
Sanofi and the Plug and Play venture fund are teaming up to explore digital technologies in the areas of nutrition and allergies. HBW Insight takes a deeper look at this partnership, as the pharma giant looks to take a lead role in European digital health innovation.
During their bi-annual meeting, Germany’s Expert Committee for Prescription was set to discuss a move from prescription to OTC status for hydrocortisone 1% for external use, and combination ibuprofen and phenylephrine hydrochloride. Get the details of the proposal with reporting from HBW Insight.
Insurers and a neurologist testifying at a May 16 Senate Finance Committee hearing on the CHRONIC Care Act praised the bill’s telehealth provisions. Committee Chairman Orrin Hatch, R-Utah, says he plans to mark up the bill, which has been under development for two years, this week.
RB’s spending on the WebMD-hosted Cold & Flu Tracker app generated an ROI three times greater than traditional digital marketing, says marketing executive Emma Howe. Similar campaigns are gaining momentum, with WebMD and Walgreens launching “Relief Advisor.”
Connected care technologies play an important role in disease prevention, but are still not used as widely as they should be. Philips’ second Future Health Index study surveyed 33,000 participants in 19 countries to compare perceptions and experiences of healthcare users across three areas – access to care, integration of health systems and adoption of connected care technologies.
A digital video game developed by Akili Interactive Labs for treating cognitive disorders has demonstrated in a pilot study its ability to improve cognitive control test scores of neurotypical children and children with sensory processing dysfunction (SPD).
Victoria Hordern and Amy Merrick discuss initiatives in the EU to help app developers navigate the unclear rules on mobile health and explain why engaging patients during product development is key.
Biogen’s chief medical officer says iPhone technology should in future be used for early warning diagnosis of Alzheimer’s Disease. Biogen CMO Alfred Sandrock has told a London neuroscience forum that constraints impeding CNS drug development include the fact diagnosis needs to be done earlier but that barrier could be mitigated in future by digital health solutions such iPhones used as “early warning” diagnostics, notably in Alzheimer’s Disease.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!